G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Ming Hong,Ming Hong,Suyang Hao,Keyur P. Patel,Hagop M. Kantarjian,Guillermo Garcia-Manero,C. Cameron Yin,L. Jeffrey Medeiros,Pei Lin,Xinyan Lu +9 more
TL;DR: The der(5;17)(p10;q10) represents a unique molecular-cytogenetic subgroup in t-MNs and, associated with complex karyotypes, likely contributes to the poor clinical outcome of these patients.
Journal ArticleDOI
Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS
Marina Konopleva,Donna E. Hogge,David A. Rizzieri,Thomas P. Cirrito,Jen Sing Liu,Steven M. Kornblau,Margarite Grable,Il-Ran Hwang,Gautam Borthakur,Allison Mankin,Carol Bivins,Guillermo Garcia-Manero,Tapan M. Kadia,David Harris,Farhad Ravandi,Michael Andreeff,Jorge E. Cortes,Robert Niecestro,Ivan Bergstein,Hagop M. Kantarjian,Arthur E. Frankel +20 more
TL;DR: Overall, SL-401 was well-tolerated at clinically active doses and anti-tumor activity, defined as blast reductions or disease stabilization, was seen in 46% of patients with relapsed or refractory AML, 55% of poor risk elderly AMl, and 43% of high risk MDS patients.
Journal ArticleDOI
Contemporary outcomes in IDH‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatment
Curtis Lachowiez,Patrick K. Reville,Hagop M. Kantarjian,Elias Jabbour,Gautam Borthakur,Naval Daver,Ghayas C Issa,Kenichi Furudate,Tomoyuki Tanaka,Sherry Pierce,Guilin Tang,Keyur Patel,Jeffrey T. Medeiros,Hussein A. Abbas,F. Haddad,Danielle Hammond,Nicholas J. Short,Abhishek Maiti,Musa Yilmaz,Koji Sasaki,Koichi Takahashi,Naveen Pemmaraju,Marina Konopleva,Guillermo Garcia-Manero,Farhad Ravandi,Tapan M. Kadia,Sanam Loghavi,Courtney D. DiNardo +27 more
TL;DR: Differing outcomes were observed in IDH1mut versus IDH2mut or N PM1mut AML which were influenced by co‐occurring NPM1 mutations and partially abrogated with venetoclax‐based therapy, and investigations incorporating molecularly targeted therapies such as IDH inhibitors remain warranted in this subgroup.
Journal ArticleDOI
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
Megan Othus,Mikkael A. Sekeres,Sucha Nand,Guillermo Garcia-Manero,Frederick R. Appelbaum,Harry P. Erba,Eli Estey +6 more
TL;DR: The absolute and relative overall survival benefits conveyed by complete remission in AML and high-risk MDS and by CR with incomplete count recovery and by hematologic improvement in MDS, following treatment with 7 + 3 versus azacytidine are quantified and compared.
Journal ArticleDOI
Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial
Koji Sasaki,Hagop M. Kantarjian,Farhad Ravandi,Nicholas J. Short,Partow Kebriaei,Xuelin Huang,Nitin Jain,Marina Konopleva,Guillermo Garcia-Manero,Richard E. Champlin,Tapan M. Kadia,Koichi Takahashi,Naval Daver,Hind Rafei,Joseph D. Khoury,Jeffrey L. Jorgensen,Sa A. Wang,Maria Khouri,Jovitta Jacob,Rebecca Garris,Susan O'Brien,Elias Jabbour +21 more
TL;DR: The combination of inotuzumab with low-intensity mini-hyper-CVD chemotherapy showed encouraging results in this patient population, and the sequential addition of blinatumomab might optimize the efficacy of the regimen, reduce its toxicities, and further improve outcomes in R-R ALL.